Frank Baldino, Jr.

Who was Frank Baldino, Jr.?

Dr. Baldino founded Cephalon in 1987 and grew it from a privately held

company to the sixth largest publicly traded biotechnology company in

the U.S., with 2005 revenue exceeding $1.2 billion. Cephalon expects

to propel its annual revenue to $2 billion by 2008 with dramatic growth

of its core products combined with new product launches, acquisitions

and industry collaborations.

Dr. Baldino has nearly two decades of scientific experience in

neurobiology, molecular biology and electrophysiology, and has authored

more than 100 publications in peer-reviewed journals such as Nature,

Journal of Neuroscience Research and Brain Research. Dr. Baldino

received his Ph.D. in pharmacology from Temple University. From

1981-1987, Dr. Baldino served as senior research biologist in the

medical products department at E.I. duPont de Nemours Company,

where he was responsible for developing research strategies for

identifying novel neuropharmaceutical agents.

Dr. Baldino Chairs the Executive Council of the Harvard Division of

Sleep Medicine, and is a member of the Board of Trustees at Temple

University and The Franklin Institute. In addition, Dr. Baldino serves

as a member of the Board of Directors for the Greater Philadelphia

Chamber of Commerce, the Eastern Technology Council, NicOx, S.A.,

PhRMA, BioAdvance Biotechnology Greenhouse Corp., Biotechnology

Industry Association (BIO), Pharmacopeia Drug Discovery, Inc., Quaker

BioVentures, L.P., Pennsylvania Biotechnology Association, and

Acusphere, Inc. He is also a member of the Healthcap Advisors Board and

the Vantage Point Venture Partners Advisory Committee. Dr. Baldino also

holds several adjunct academic appointments, and serves on the

Muhlenberg College Board of Observers.